Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Andreasson Ulf) "

Sökning: WFRF:(Andreasson Ulf)

Sortera/gruppera träfflistan
  • Katona, Gergely, et al. (författare)
  • Conformational regulation of charge recombination reactions in a photosynthetic bacterial reaction center
  • 2005
  • Ingår i: Nature Structural and Molecular Biology. - Nature Publishing Group. - 1545-9993. ; 12:7, s. 1-630
  • Tidskriftsartikel (refereegranskat)abstract
    • In bright light the photosynthetic reaction center (RC) of Rhodobacter sphaeroides stabilizes the P(+)(870).Q(-)(A) charge-separated state and thereby minimizes the potentially harmful effects of light saturation. Using X-ray diffraction we report a conformational change that occurs within the cytoplasmic domain of this RC in response to prolonged illumination with bright light. Our observations suggest a novel structural mechanism for the regulation of electron transfer reactions in photosynthesis.
  • Alves, Guido, et al. (författare)
  • Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.
  • 2013
  • Ingår i: Journal of neurology, neurosurgery, and psychiatry. - 1468-330X. ; 84:5, s. 537-43
  • Tidskriftsartikel (refereegranskat)abstract
    • In Parkinson's disease (PD), the motor presentation characterised by postural instability/gait difficulties (PIGD) heralds accelerated motor, functional and cognitive decline, as compared with the more benign tremor-dominant (TD) variant. This makes the PIGD complex an attractive target for the discovery of prognostic biomarkers in PD.
  • Andreasson, Ulf, 1968-, et al. (författare)
  • A Practical Guide to Immunoassay Method Validation.
  • 2015
  • Ingår i: Frontiers in neurology. - 1664-2295. ; 6
  • Tidskriftsartikel (refereegranskat)abstract
    • Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer's disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well.
  • Bjerke, Maria, 1977-, et al. (författare)
  • Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.
  • 2010
  • Ingår i: International journal of Alzheimer's disease. - 2090-0252. ; 2010
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of beta-amyloid (Abeta(42)). However, a high discrepancy between different centers in measured Abeta(42) levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured Abeta(42) level. Methods. Aliquots of CSF samples were either treated differently prior to Abeta(42) measurement or analyzed using different commercially available xMAP or ELISA assays. Results. Confounding factors affecting CSF Abeta(42) levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.
  • Bos, I., et al. (författare)
  • Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
  • 2019
  • Ingår i: Alzheimers & Dementia. - 1552-5260. ; 15:5, s. 644-654
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE) e4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng), neurofilament light (NFL), YKL-40, and total tau (T-tau). Methods: We included 770 individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD)-type dementia from the EMIF-AD Multimodal Biomarker Discovery study. We tested the association of Ng, NFL, YKL-40, and T-tau with A beta status (Ab beta- vs. A beta+), clinical diagnosis APOE epsilon 4 carriership, baseline cognition, and change in cognition. Results: Ng and T-tau distinguished between A beta+ from A beta- individuals in each clinical group, whereas NFL and YKL-40 were associated with A beta+ in nondemented individuals only. APOE epsilon 4 carriership did not influence NFL, Ng, and YKL-40 in A beta+ individuals. NFL was the best predictor of cognitive decline in A beta+ individuals across the cognitive spectrum. Discussion: Axonal degeneration, synaptic dysfunction, astroglial activation, and altered tau metabolism are involved already in preclinical AD. NFL may be a useful prognostic marker. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
  • Bridel, Claire, et al. (författare)
  • Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
  • 2019
  • Ingår i: JAMA neurology. - 2168-6157. ; 76:9, s. 1035-1048
  • Tidskriftsartikel (refereegranskat)abstract
    • Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date.To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions.PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC.Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex.Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept.The cNfL levels adjusted for age and sex across diagnoses.Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes.These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.
  • Hansson, Sarah, 1976-, et al. (författare)
  • Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
  • 2009
  • Ingår i: Journal of Alzheimer's disease : JAD. - 1387-2877. ; 16:2, s. 389-97
  • Tidskriftsartikel (refereegranskat)abstract
    • Amyloid-beta(Abeta) aggregation is a major hallmark of Alzheimer's disease (AD). Previous studies have suggested that only unbound Abeta can take part in the aggregation process. Therefore, endogenous Abeta-binding proteins may have an important role in preventing AD. Here, we analyzed cerebrospinal fluid (CSF) samples from 35 subjects with AD, 18 subjects with frontotemporal dementia (FTD) and 29 non-demented controls to test if reduced Abeta-binding capacity in CSF is a specific feature of AD. A panel of known Abeta-binding CSF proteins, including beta-trace/prostaglandin D2 synthase (beta-trace), transthyretin (TTR), cystatin C (CysC) and alpha(1)-antitrypsin (AAT), were quantified and related to diagnosis and CSF levels of Abeta(1-38), Abeta(1-40) and Abeta(1-42). AD patients displayed a mild reduction in the CSF levels of beta-trace (p=0.020), CysC (p=0.017), AAT (p=0.019) and TTR (p=0.012) compared with controls. While the reductions in AAT and TTR were AD-specific, the levels of beta-trace and CysC were also reduced in FTD. As expected, CSF Abeta(1-42) was reduced in AD compared with controls (p=0.00005) and with FTD patients (p=0.015). Positive correlations between Abeta(1-42) and beta-trace, CysC and TTR, respectively, were seen only in the AD group, suggesting that deficient Abeta-binding capacity in CSF may contribute to the amyloidogenic process in AD.
  • Holtta, Mikko, et al. (författare)
  • Evaluating Amyloid-beta Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease
  • 2013
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 8:6
  • Tidskriftsartikel (refereegranskat)abstract
    • The current study evaluated amyloid-beta oligomers (A beta o) in cerebrospinal fluid as a clinical biomarker for Alzheimer's disease (AD). We developed a highly sensitive A beta o ELISA using the same N-terminal monoclonal antibody (82E1) for capture and detection. CSF samples from patients with AD, mild cognitive impairment (MCI), and healthy controls were examined. The assay was specific for oligomerized A beta with a lower limit of quantification of 200 fg/ml, and the assay signal showed a tight correlation with synthetic A beta o levels. Three clinical materials of well characterized AD patients (n = 199) and cognitively healthy controls (n = 148) from different clinical centers were included, together with a clinical material of patients with MCI (n = 165). A beta o levels were elevated in the all three AD-control comparisons although with a large overlap and a separation from controls that was far from complete. Patients with MCI who later converted to AD had increased A beta o levels on a group level but several samples had undetectable levels. These results indicate that presence of high or measurable A beta o levels in CSF is clearly associated with AD, but the overlap is too large for the test to have any diagnostic potential on its own.
  • Kalm, Marie, 1981-, et al. (författare)
  • C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning.
  • 2016
  • Ingår i: Oncotarget. - 1949-2553. ; 7:15, s. 19382-94
  • Tidskriftsartikel (refereegranskat)abstract
    • Radiotherapy in the treatment of pediatric brain tumors is often associated with debilitating late-appearing adverse effects, such as intellectual impairment. Areas in the brain harboring stem cells are particularly sensitive to irradiation (IR) and loss of these cells may contribute to cognitive deficits. It has been demonstrated that IR-induced inflammation negatively affects neural progenitor differentiation. In this study, we used mice lacking the third complement component (C3-/-) to investigate the role of complement in a mouse model of IR-induced injury to the granule cell layer (GCL) of the hippocampus. C3-/- and wild type (WT) mice received a single, moderate dose of 8 Gy to the brain on postnatal day 10. The C3-/- mice displayed 55 % more microglia (Iba-1+) and a trend towards increase in proliferating cells in the GCL compared to WT mice 7 days after IR. Importantly, months after IR C3-/- mice made fewer errors than WT mice in a reversal learning test indicating better learning capacity in C3-/- mice after IR. Notably, months after IR C3-/- and WT mice had similar GCL volumes, survival of newborn cells (BrdU), microglia (Iba-1) and astrocyte (S100β) numbers in the GCL. In summary, our data show that the complement system contributes to IR-induced loss of proliferating cells and maladaptive inflammatory responses in the acute phase after IR, leading to impaired learning capacity in adulthood. Targeting the complement system is hence promising for future strategies to reduce the long-term adverse consequences of IR in the young brain.
Skapa referenser, mejla, bekava och länka
fritt online (32)
Typ av publikation
tidskriftsartikel (181)
forskningsöversikt (8)
doktorsavhandling (4)
bok (2)
rapport (2)
konferensbidrag (2)
visa fler...
bokkapitel (1)
licentiatavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (178)
övrigt vetenskapligt (26)
populärvet., debatt m.m. (5)
Andreasson, Ulf, 196 ... (114)
Zetterberg, Henrik, ... (111)
Blennow, Kaj, 1958-, (101)
Blennow, Kaj (45)
Zetterberg, Henrik, (44)
Portelius, Erik, 197 ... (43)
visa fler...
Hansson, Oskar, (30)
Mattsson, Niklas, 19 ... (22)
Andreasson, U (20)
Minthon, Lennart, (19)
Blennow, K (18)
Mattsson, Niklas, (18)
Zetterberg, H (17)
Brinkmalm, Gunnar, (14)
Wallin, Anders, 1950 ... (11)
Andreasen, Niels, (11)
Olsson, Bob, 1969-, (10)
Shaw, Leslie M (10)
Wallin, Anders, (10)
Brinkmalm-Westman, A ... (9)
Gustavsson, Mikael K ... (9)
Lewczuk, Piotr (8)
Andreasen, N, (8)
Andréasson, Sten, (7)
Teunissen, Charlotte ... (7)
Svensson, Johan, (7)
Johansson, Per, (7)
Vanmechelen, Eugeen (7)
Hagberg, Lars, 1951- ... (6)
Pannee, Josef, 1979- ... (6)
Trojanowski, John Q (6)
Engelborghs, Sebasti ... (6)
Verbeek, Marcel M (6)
Lewczuk, P (6)
Lautner, Ronald, (6)
Londos, Elisabet, (5)
Helmersson, Ulf (5)
Ponjavic, Vesna, (5)
Abrahamson, Magnus, (5)
Olsson, Maria, (5)
Constantinescu, Radu ... (5)
Constantinescu, Radu ... (5)
Ekström, Ulf, (5)
Cullen, Nicholas C, (5)
Janelidze, Shorena, (5)
Hansson, O (5)
Vanderstichele, Hugo (5)
Andréasson, Ester, (5)
Parnetti, Lucilla (5)
Engelborghs, S (5)
visa färre...
Göteborgs universitet (145)
Lunds universitet (46)
Karolinska Institutet (19)
Uppsala universitet (13)
Linköpings universitet (12)
Luleå tekniska universitet (5)
visa fler...
Chalmers tekniska högskola (5)
Umeå universitet (4)
Kungliga Tekniska Högskolan (2)
Örebro universitet (2)
Linnéuniversitetet (2)
RISE (1)
Naturhistoriska riksmuseet (1)
visa färre...
Engelska (187)
Svenska (12)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (178)
Samhällsvetenskap (9)
Teknik (8)
Naturvetenskap (5)
Humaniora (2)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy